CEL-SCI Corporation CVM today announced that
its collaborators at the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health, USA, have
submitted for publication to a prestigious scientific journal the
results from efficacy studies in animals of L.E.A.P.S. (Ligand Epitope
Antigen Presentation System) H1N1 activated dendritic cells (DCs) to
treat the H1N1 bird flu virus. This work was conducted by scientists at
the NIAID in collaboration with scientists from CEL-SCI. The publication
addresses how the specific and selectively directed activity induced by
the LEAPS-activated DCs could be used in the possible treatment and
mitigation of pandemic flu.
This work may possibly also be applicable to the new
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in